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Crizotinib is an oral tyrosine kinase inhibitor that can inhibit anaplastic lymphoma kinase (ALK), hepatocyte 
growth factor receptor, proto-oncogene tyrosine kinase c-ROS 
1, recepteur d’origine nantais, among other kinases.1 On 
August 26, 2011, the Food and Drug Administration (FDA) 
granted accelerated approval to crizotinib for the treatment 
of patients with locally advanced or metastatic non–small-
cell lung cancer (NSCLC) that is ALK-positive as detected 
by an FDA-approved test; the test approved was the Vysis 
ALK Break-Apart FISH probe (Abbott Molecular, Inc., Des 
Plaines, IL). Crizotinib has been studied in phase I, II, and 
III trials in more than 300 human subjects.2,3 The drug has 
bioavailability and a favorable pharmacokinetic profile.2 The 
major side effects include visual field disturbances, nausea, 
vomiting, diarrhea, edema, liver function test abnormali-
ties, among others.2,4,5 Less than a third of patients develop 
significant adverse events that require dose interruptions or 
reductions.3
Esophageal disorders, and more specifically severe 
esophagitis, have not been commonly associated with the use 
of crizotinib. In the current report, we describe the association 
of crizotinib and clinically significant esophagitis.
CASE REPORT
An 80-year-old, never-smoker, Chinese woman pre-
sented to medical attention with chest pain and hemoptysis. 
Diagnostic workup included imaging studies that demon-
strated a 7.2-cm right upper lobe mass that compressed the 
right upper lobe bronchus along with osseous destruction in 
the right fifth rib. Endobronchial ultrasound with biopsy of 
the mass demonstrated a squamous cell carcinoma. The tumor 
was found to have wild-type EGFR and KRAS. Vysis ALK 
Break-Apart FISH probe disclosed 16% positive nuclei for an 
ALK rearrangement.
The patient was started on crizotinib 250-mg capsules 
twice a day and developed visual changes and nausea 
(relieved by ondansetron) within the first week of treatment. 
Within 2 weeks of use, she reported a sensation of “food 
being stuck” in her lower thoracic/upper abdominal area. 
She had no history of gastroesophageal reflux disease. After 
a 10-day trial of a proton pump inhibitor (omeprazole), the 
patient reported that she continued to have dysphagia but was 
now also experiencing odynophagia. Repeat imaging studies 
disclosed severe lower esophageal wall thickening (Fig. 1). 
Crizotinib was discontinued at the 1-month mark of treatment. 
Esophagogastroduodenoscopy highlighted an impression of 
soft esophageal extrinsic compression in the middle third of 
the esophagus. Pathologic findings from esophageal biopsies 
demonstrated active esophagitis with surface ulceration, 
fibrinopurulent exudate, and granulation tissue formation 
(Fig. 2). Within 10 days of stopping crizotinib, the patient’s 
symptoms had completely resolved and the patient reported 
that she was able to follow a normal diet and had no dysphagia 
nor odynophagia. Crizotinib was not reintroduced because of 
tumor progression.
DISCUSSION
The largest published cohort of patients with ALK-
positive NSCLC included 149 patients from the original 
phase I trial of crizotinib.2,3 Among these, 144 (97%) had 
adverse events. The most commonly reported events were 
visual effects (64% of patients), nausea (56%), diarrhea 
(50%), vomiting (39%), peripheral edema (30%), consti-
pation (28%), dizziness (21%), anorexia (16%), fatigue 
(16%), increased alanine aminotransferase (12%), rash 
(11%), dysgeusia (11%), and increased aspartate ami-
notransferase (10%).3 Among the Common Terminology 
Criteria for Adverse Events (CTCAE) grade 3 and 4 events 
reported—which totaled 24% of the patients experiencing 
it—neutropenia (6%), increased alanine aminotransferase 
(4%), hypophosphatemia (4%), lymphopenia (4%), aspar-
tate aminotransferase (3%), pneumonitis (2%), and fatigue 
(1%) were the most common.3 The FDA label for crizotinib 
expands the adverse event profile incorporating data for 255 
patients treated as part of the phase I and II clinical trials of 
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crizotinib, and the adverse event frequencies mirror those of 
the aforementioned report.
Esophageal disorders—listed as dyspepsia, dysphagia, 
epigastric discomfort or pain or burning, esophagitis, esoph-
ageal obstruction or pain or spasm or ulcer, gastroesophageal 
reflux, odynophagia, and reflux esophagitis—were reported 
to occur in 20% of the 255 patients, but in only 11% were 
they attributed to crizotinib. In addition, no cases of CTCAE 
grade 3 or 4 esophageal disorder occurrences were attributed 
to crizotinib. A detailed review of the phase I trial report 
indicates that 1 out of the 149 (0.6%) patients had grade 3 
dysphagia.
The current report describes the rapid development 
of a CTCAE grade 3 esophagitis—manifested as dysphagia 
and odynophagia—without preceding esophageal disease in 
a patient treated with crizotinib 250-mg capsules twice daily. 
The clinical, radiographic, and pathologic findings confirmed 
severe esophagitis. The clinical symptoms improved with dis-
continuation of crizotinib.
In summary, we report the first direct association of 
severe esophagitis as an adverse event of crizotinib. As the use 
of crizotinib expands to a larger population of patients with 
ALK-positive NSCLC, it is likely that rare adverse events will 
be encountered in clinical practice. The timely reporting of 
novel adverse events from crizotinib will improve management 
of patients receiving this valuable tyrosine kinase inhibitor.
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FIGURE 1.  PET-CT images disclosing severe circumferential lower esophageal wall thickening associated with mild mural FDG 
avidity and associated luminal narrowing. A, PET image, (B) CT images, and (C), fused images. The arrow indicates the esopha-
geal abnormality. PET, positron emission tomography, CT, computed tomography; FDG, fluorodeoxy-D-glucose.
FIGURE 2.  Midesophagus mucosal 
biopsies (hematoxylin and eosin stain). 
Representative images taken at (A) 200× 
and (B) 400× magnification demonstrate 
active esophagitis with surface ulceration 
and fibrinopurulent exudate (blue arrows), 
and granulation tissue formation (black 
arrows). The predominantly neutrophilic 
infiltrate has admixed eosinophils. Stains 
for microorganisms were negative (not 
shown).
